ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 761

Analysis of Biomarkers in Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy

Nico Wulffraat1, Hermine Brunner2, Nicolino Ruperto3, Pierre Quartier4, Riva Brik5, Liza McCann5, Huri Ozdogan5, Lidia Rutkowska-Sak5, Rayfel Schneider2, Valeria Gerloni5, Liora Harel6, Maria Hilário2, Kristin Houghton2, Rik Joos5, Daniel Kingsbury2, Arndt Brachat7, Stephan Bek7, Martin Schumacher7, Marie-Anne Valentin8, N.R Nirmala9, Hermann Gram7, Ken Abrams10, Alberto Martini11 and D. J. Lovell12, 1PRINTO, Genoa, Italy, 2Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, 3Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, 4Pediatria II, Istituto Giannina Gaslini, Genoa, Italy, 5Paediatric Rheumatology International Trials Organization (PRINTO), Genova, Italy, 6Pediatric Rheumatology unit, Schneider Children's Medical Center, Tel Aviv University, Petach Tikvah, Israel, 7Novartis Institutes for Biomedical Research, Basel, Switzerland, 8Biomarker Development, Novartis Pharma AG, Basel, Switzerland, 9Novartis Institutes for Biomedical Research, Cambridge, MA, 10Novartis Pharmaceuticals Corporation, New Jersey, 11Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, 12Cincinnati Children's Hospital, Cincinnati, OH

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Interleukins (IL) and juvenile idiopathic arthritis (JIA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology: Clinical and Therapeutic Disease I: Juvenile Idiopathic Arthritis I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Systemic Juvenile Idiopathic Arthritis (SJIA) is a severe disabling subtype of Juvenile Idiopathic Arthritis characterized by arthritis plus systemic symptoms, such as high fever, rash, serositis, and lymphadenopathy. Among others, interleukin (IL)-1β is an inflammatory cytokine that plays a dominant role in SJIA and several other autoinflammatory conditions, with anti-IL-1β therapy showing good efficacy in many of these settings. Canakinumab (CAN) is a high-affinity selective human monoclonal antibody targeted against IL-1β. Levels of inflammatory biomarkers and gene expression profiles of patients with active SJIA before and during canakinumab treatment were studied from patients aged 2 to <20 years participating in 2 phase III trials.

Methods:

Serial measurements of levels of cytokines and proteins involved in inflammation (IL6; IL18; S100A8, A9 and A12) were made at baseline and at Days 3 and 29 after initiation of CAN treatment.  Whole blood samples and DNA microarrays were used to characterize the early (Day 3) transcriptional response to CAN treatment and to predict efficacy.

Results:  

Protein markers: The median levels of IL-6 were strongly reduced; 7.2 fold reduction in the first trial (p=0.012) and 4.9 fold in the second trial (p=0.000046) by Day 29, while IL-18 levels remained largely unchanged by Day 29. Among the S100 proteins, median S100A9 levels were reduced by 3.4 fold in the first trial (p=0.0078) and 4.3 fold in the second trial (p=0.016). S100A8 and S100A9 proteins did not show consistent behaviors across the two trials.

Gene Expression:

For all comparisons, the number of down regulated genes was much larger than the number of upregulated genes upon treatment, suggesting that the active disease state was mainly characterized by transcriptional activation of “disease genes”. Transcriptional changes upon CAN treatment at Day 3 were highly consistent between the two trials. Subjects who showed strong transcriptional changes (primarily down regulation, >2x, p=0.05) also showed a strong adapted pediatric ACR response (≥ACR50) at Day 15, while subjects that did not reach ACR50 by Day 15 showed a much weaker transcriptional response at Day 3. Strongly responsive genes included many known inflammation and neutrophil-related genes, including IL-1β, encoding the CAN target.  A set of transcripts was identified for which baseline expression levels predicted a subgroup of strong (≥ACR70) responders at Day 15. However, another subgroup of strong responders was indistinguishable from weak responders (

Conclusion:

CAN treatment resulted in a strong reduction of elevated baseline IL6 protein levels in patients with active SJIA, while IL18 protein levels remained largely unchanged until Day 29 of the treatment period. Many patients who showed a strong clinical benefit already at Day 15 were characterized by high baseline expression levels of inflammatory and neutrophil associated genes which were repressed after 3 days of CAN treatment. A second, smaller, group of patients showing good clinical response did, however, not show this pattern, suggesting the existence of mechanistically different subpopulations in this disease.


Disclosure:

N. Wulffraat,

Novartis ,

9;

H. Brunner,

Novartis, UCB, Genentech, Jansen, GSK and Medimmune,

5,

Participant in Scientific Advisory Committee for Canakinumab program in SJIA,

9;

N. Ruperto,

Abbott, Astrazeneca, Bristol Myers and Squibb, Centocor Research & Development, Eli Lilly and Company, “Francesco Angelini” s.p.a,

2,

Astrazeneca, Novartis, Bristol Myers and Squibb, Roche, Janssen Bilogics B.V.,

8,

Glaxo Smith & Kline, Italfarmaco, Merck Serono, Novartis, Pfizer Inc., Regeneron, Roche, Sanofi Aventis, Schwarz Biosciences GmbH, Xoma, Wyeth Pharmaceuticals Inc,

2;

P. Quartier,

Novartis,

8;

R. Brik,
None;

L. McCann,
None;

H. Ozdogan,

Novartis ,

8;

L. Rutkowska-Sak,
None;

R. Schneider,

Hoffman-La-Roche,

5,

Hoffman-La-Roche,

8;

V. Gerloni,
None;

L. Harel,
None;

M. Hilário,
None;

K. Houghton,
None;

R. Joos,
None;

D. Kingsbury,
None;

A. Brachat,

Novartis ,

1,

Novartis ,

3;

S. Bek,

Novartis ,

3;

M. Schumacher,

Novartis ,

3;

M. A. Valentin,

Novartis ,

1,

Novartis ,

3;

N. R. Nirmala,

Novartis ,

1,

Novartis ,

3;

H. Gram,

Novartis ,

3;

K. Abrams,

Novartis ,

1,

Novartis ,

3;

A. Martini,

Abbott, Astrazeneca, Bristol Myers and Squibb, Centocor Research & Development, Eli Lilly and Company, Xoma, Wyeth Pharmaceuticals, ,

2,

Astrazeneca, Novartis, Bristol Myers and Squibb, Glaxo Smith & Kline,

8,

“Francesco Angelini” s.p.a, Glaxo Smith & Kline, Italfarmaco, Merck Serono, Novartis, Pfizer Inc., Regeneron, Roche, Sanofi Aventis, Schwarz Biosciences GmbH,

2;

D. J. Lovell,

Astra-Zeneca, Centocor, Bristol Meyers Squibb, Abbott, Pfizer, Regeneron, Hoffman La-Roche, Novartis, UBC, Xoma, Genentech,

5,

Wyeth Pharmaceuticals,

8,

Amgen, Forest Research,

9,

Arthritis & Rheumatism,

9.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-biomarkers-in-systemic-juvenile-idiopathic-arthritis-patients-on-canakinumab-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology